Related Experiment Video
Updated: Jan 17, 2026

06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
646
Nomogram Based on A-To-I RNA Editing for Predicting Overall Survival in Patients With Breast Cancer
Yangyang Zhang1, Jia Zhou2, Hong Li3
1General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Journal of Cellular and Molecular Medicine
|September 25, 2025
Summary
Adenosine-to-inosine RNA editing (ATIRE) shows promise as a biomarker for breast cancer (BRCA). A new ATIRE-based prognostic model accurately predicts patient survival, aiding personalized treatment decisions.
Area of Science:
- Molecular Biology
- Genomics
- Oncology
Background:
- Adenosine-to-inosine RNA editing (ATIRE) is prevalent in eukaryotes and linked to various cancers.
- While some ATIRE sites predict cancer prognosis, their role in breast cancer (BRCA) is unclear.
Purpose of the Study:
- To investigate the diagnostic and prognostic potential of ATIRE sites in BRCA.
- To develop and validate a prognostic model for BRCA patients based on ATIRE sites.
Main Methods:
- Utilized TCGA data for BRCA patients, dividing them into training and validation cohorts.
- Employed univariate Cox, Lasso, and multivariate Cox regression to identify prognostic ATIRE sites.
- Constructed a prognostic model and risk score, validated using nomograms, calibration, and decision curves.
Main Results:
- Identified nine ATIRE sites associated with BRCA prognosis, forming a predictive model.
- High-risk scores correlated with significantly shorter median survival times.
- Five ATIRE sites showed correlation with gene expression; four were upregulated in tumor tissues.
Conclusions:
- An ATIRE-based prognostic model can accurately predict survival in BRCA patients.
- This model offers a novel tool for personalized clinical decision-making in BRCA management.
Related Concept Videos
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
Dosage Regimen Designs: Nomograms and Tabulations
181
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
181
Kaplan-Meier Approach
577
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
577

